SEARCH

SEARCH BY CITATION

References

  • 1
    Heron MP, Smith BL, Division of Vital Statistics. Deaths: Leading Causes for 2003. National Vital Statistics Reports 2007; 55: 10 and 13, Tables E and F (accessed online at http://www.cdc.gov on June 2007).
  • 2
    Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 3318.
  • 3
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 70514.
  • 4
    Fontana RJ, ASF Lok. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002; 36: S5764.
  • 5
    Everson GT, Lauriski S, DeSanto J, et al. Quantitative tests (QLFTs) detect impaired hepatic function in a high proportion of chronic hepatitis C patients with fibrosis or compensated cirrhosis and may predict risk of cirrhosis, splenomegaly, and varices. Hepatology 2003; 38: 304A.
  • 6
    Everson GT, Shiffman ML, Hoefs JC, et al. Quantitative liver function tests predict sustained virologic response to retreatment with peginterferon alfa-2a plus ribavirin: results of the lead-in phase of the HALT-C trial. Hepatology 2004; 40: 313A.
  • 7
    Everson GT, Shiffman ML, Sterling RK, et al. Hepatic function improves after sustained virologic response in hepatitis C patients with advanced fibrosis and cirrhosis: results of the lead-in phase of the HALT-C Trial. Hepatology 2005; 42: 697A.
  • 8
    Shrestha R, McKinley C, Showalter R, et al. Quantitative Liver Function Tests (QLFTs) define the functional severity of liver disease in early stage cirrhosis. Liver Transpl Surg 1997; 3: 16673.
  • 9
    Lee WM, Dienstag JL, Lindsay KL, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004; 25: 47292.
  • 10
    Everson GT, Hoefs JC, Seeff LB, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C Trial. Hepatology 2006; 44: 167584.
  • 11
    DeMark BR, Everson GT, Klein PD, Showalter RB, Kern F. A method for the accurate measurement of isotope ratios of chenodeoxycholic and cholic acids in serum. J Lipid Res 1982; 23: 20410.
  • 12
    Everson GT. Steady-state kinetics of serum bile acids in healthy human subjects: single and dual isotope techniques using stable isotopes and mass spectrometry. J Lipid Res 1987; 28: 23852.
  • 13
    Chapra SC, Canale RP Numerical Methods for Engineers,. 2nd edn. New York: McGraw-Hill, 1988: 38798.
  • 14
    De Boor C. A Practical Guide to Splines. New York: Springer, 2002.
  • 15
    Wahba G. Spline Models for Observational Data. Philadelphia: Society for Industrial and Applied Mathematics, 1990.
  • 16
    Hosmer DW, Lemeshow S. Applied Logistic Regression, 2nd edn. New York, NY: John Wiley and Sons, 2000.
  • 17
    SAS Institute, Inc, SAS/STAT® 9.1 User’s Guide, Cary, NC: SAS Institute, Inc, 2004.
  • 18
    Rosner B. Fundamentals of Biostatistics, 3rd edn. Belmont, CA: Duxbury Press, 1990.
  • 19
    Lotterer E, Hogel J, Gaus W, Fleig W, Bircher J. Quantitative liver function tests as surrogate markers for end-points in controlled clinical trials: a retrospective feasibility study. Hepatology 1997; 26: 142633.
  • 20
    Reichen J. Assessment of hepatitic function with xenobiotics. Semin Liver Dis 1995; 15: 189201.
  • 21
    Tanaka E, Breimer DD. In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease. J Clin Pharm Ther 1997; 22: 23749.
  • 22
    Figg W, Dukes G, Lesesne H, et al. Comparison of quantitative methods to assess hepatic function: Pugh’s classification, indocyanine green, antipyrine, and dextromethorphan. Pharmacotherapy 1995; 15: 693700.
  • 23
    Gilmore IT, Thompson RPH. Plasma clearance of oral and intravenous cholic acid in subjects with and without chronic liver disease. Gut 1980; 21: 1237.
  • 24
    Nordlinger B, Parquet M, Infante R, et al. Noninvasive measurement of nutrient portal blood shunting: an experimental study with [ 14C ] ursodeoxycholic acid. Hepatology 1982; 2: 4129.
  • 25
    Yu M-L, Lin S-M, Lee C-M, et al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology 2006; 44: 108697.
  • 26
    Afdahl NH. Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology 2003; 37: 9724.
  • 27
    Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 98692.
  • 28
    Poynard T, Imbert-Bismut F, Munteanu M, Ratzui V. FibroTest-FibroSureTM: towards a universal biomarker of liver fibrosis? Expert Rev Mol Diagn 2005; 5: 1521.
  • 29
    Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005; 42: 28292.
  • 30
    Perri F, Marras RM, Ricciardi R, Quitadamo M, Andrulli A. 13C-breath tests in hepatology (cytosolic function). Eur Rev Med Pharmacol Sci 2004; 8: 479.
  • 31
    Herold C, Heinz R, Niedobitek G, Schneider T, Hahn EG, Schuppan D. Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C. Liver 2001; 21: 2605.
  • 32
    Giannini EG, Fasoli A, Borro P, et al. 13C-galactose breath test and 13C-aminopyrine breath test for the study of liver function in chronic liver disease. Clin Gastroenterol Hepatol 2005; 3: 27985.
  • 33
    Slanar O, Aubrecht J, Perlik F. Noninvasive evaluation of portal-systemic shunting by glyceryl trinitrate. Physiol Res 2002; 51: 4136.
  • 34
    Plestina S, Pulanic R, Kralik M, Plestina S, Samarzija M. Color Doppler ultrasonography is reliable in assessing the risk of esophageal variceal bleeding in patients with liver cirrhosis. Wien Klin Wochenschr 2005; 117: 7117.
  • 35
    Schneider ARJ, Teuber G, Kriener S, Caspary WF. Noninvasive assessment of liver steatosis, fibrosis, and inflammation in chronic hepatitis C virus infection. Liver Int 2005; 25: 11505.
  • 36
    Sandrin L, Fourquet B, Hasquenoph J-M, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 170513.
  • 37
    Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 34350.
  • 38
    Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 4854.
  • 39
    Rouviere O, Yin M, Dresner MA, Rossman LJ, Fidler JL, Ehman RL. MR elastography of the liver: preliminary results. Radiology 2006; 240: 4408.
  • 40
    Senzolo M, Burra P, Cholongitas E, et al. The transjugular route: the key hole to the liver world. Dig Liver Dis 2007; 39: 10516.